Abstract
Next to water, tea is the most popular beverage in the world. The most abundant and active compound in green tea is (-)-epigallocatechin-3-gallate (EGCG), which is extensively studied for its cancer-preventive and anti-cancer activities as well as its cellular targets. One potential molecular target of EGCG is the proteasome. While molecular docking and structure-activity relationship (SAR) analysis suggests that the ester carbon of EGCG is important for mediating its proteasome-inhibitory activity, EGCG is very unstable under physiological conditions. Therefore, a series of analogs were synthesized aiming to improve stability and bioavailability of EGCG. Among them, peracetate-protected or the prodrug of EGCG was found to have increased bioavailability, stability, and proteasome-inhibitory activities against various human cancer cells and tumors compared to EGCG, suggesting its potential use for cancer prevention and treatment. Epidemiological studies have indicated that green tea consumption is associated with the reduced risk of cancers, especially associated with the reduced risk of late stage of cancers. This risk reduction may be attributed not only to proteasome inhibition, but also to numerous other intracellular molecules targeted by EGCG that are involved in cell cycle regulation, apoptosis, angiogenesis, and metastasis.
Keywords: Proteasome inhibitors, drug discovery, chemoprevention, targeted therapy
Current Cancer Drug Targets
Title: Green Tea Polyphenols as Proteasome Inhibitors: Implication in Chemoprevention
Volume: 11 Issue: 3
Author(s): H. Yang, K. Landis-Piwowar, T. H. Chan and Q. P. Dou
Affiliation:
Keywords: Proteasome inhibitors, drug discovery, chemoprevention, targeted therapy
Abstract: Next to water, tea is the most popular beverage in the world. The most abundant and active compound in green tea is (-)-epigallocatechin-3-gallate (EGCG), which is extensively studied for its cancer-preventive and anti-cancer activities as well as its cellular targets. One potential molecular target of EGCG is the proteasome. While molecular docking and structure-activity relationship (SAR) analysis suggests that the ester carbon of EGCG is important for mediating its proteasome-inhibitory activity, EGCG is very unstable under physiological conditions. Therefore, a series of analogs were synthesized aiming to improve stability and bioavailability of EGCG. Among them, peracetate-protected or the prodrug of EGCG was found to have increased bioavailability, stability, and proteasome-inhibitory activities against various human cancer cells and tumors compared to EGCG, suggesting its potential use for cancer prevention and treatment. Epidemiological studies have indicated that green tea consumption is associated with the reduced risk of cancers, especially associated with the reduced risk of late stage of cancers. This risk reduction may be attributed not only to proteasome inhibition, but also to numerous other intracellular molecules targeted by EGCG that are involved in cell cycle regulation, apoptosis, angiogenesis, and metastasis.
Export Options
About this article
Cite this article as:
Yang H., Landis-Piwowar K., H. Chan T. and P. Dou Q., Green Tea Polyphenols as Proteasome Inhibitors: Implication in Chemoprevention, Current Cancer Drug Targets 2011; 11 (3) . https://dx.doi.org/10.2174/156800911794519743
DOI https://dx.doi.org/10.2174/156800911794519743 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Innovative Cancer Drug Targets: A New Horizon in Oncology
Cancer remains one of the most challenging diseases, with its complexity and adaptability necessitating continuous research efforts into more effective and targeted therapeutic approaches. Recent years have witnessed significant progress in understanding the molecular and genetic basis of cancer, leading to the identification of novel drug targets. These include, but ...read more
Role of Immune and Genotoxic Response Biomarkers in Tumor Microenvironment in Cancer Diagnosis and Treatment
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process of exploring and investigating the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
The Impact of Cancer Neuroscience on Novel Brain Cancer Treatment
Brain cancer remains one of the most challenging malignancies due to its complexity and resistance to conventional therapies. Recent advancements in cancer neuroscience have transformed our understanding of the brain's tumor microenvironment, offering promising insights into novel treatments. By studying the intricate interactions between cancer cells and the nervous system, ...read more
Unraveling the Tumor Microenvironment and Potential Therapeutic Targets: Insights from Single-Cell Sequencing and Spatial Transcriptomics
This special issue will focus on unraveling the complexities of the tumor microenvironment (TME) and identifying key biomarkers for potential therapeutic targets using advanced multi-omics techniques, such as single-cell sequencing and spatial transcriptomics. We seek original research and comprehensive reviews that investigate the heterogeneity and dynamics of the TME, emphasizing ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Sphingolipids as Targets for Microbial Infections
Mini-Reviews in Medicinal Chemistry Current Treatments of Muco-Cutaneous Herpes Simplex Virus Infections
Current Medicinal Chemistry - Anti-Infective Agents Cytochrome P450 Gene Polymorphism and Cancer
Current Drug Metabolism Research Progress of DCLK1 Inhibitors as Cancer Therapeutics
Current Medicinal Chemistry The Potential Role of Pharmacogenomic and Genomic in the Adjuvant Treatment of Early Stage Non Small Cell Lung Cancer
Current Genomics Transductional Targeting with Recombinant Adenovirus Vectors
Current Gene Therapy Synthesis and Antioxidant Evaluation of a New Class of Thienopyrimidine-rhodanine Hybrids
Letters in Drug Design & Discovery Aspirin Use on Incidence and Mortality of Gastrointestinal Cancers: Current State of Epidemiological Evidence
Current Pharmaceutical Design A Five-gene Signature based on MicroRNA for Predicting Prognosis and Immunotherapy in Stomach Adenocarcinoma
Current Medicinal Chemistry SnoN: Bridging Neurobiology and Cancer Biology
Current Molecular Medicine Gut Microbiota as an Emerging Therapeutic Avenue for the Treatment of Nonalcoholic Fatty Liver Disease
Current Pharmaceutical Design Nitric Oxide and Dietary Factors: Part III Minerals, Vitamins and Other Dietary and Lifestyle Factors
Vascular Disease Prevention (Discontinued) Selective Modulation of Aβ42 Production in Alzheimers Disease: Non-Steroidal Anti-Inflammatory Drugs and Beyond
Current Pharmaceutical Design Perspectives in Breast and Ovarian Cancer Chemotherapy by Nanomedicine Approach: Nanoformulations in Clinical Research
Current Medicinal Chemistry Transmembrane Protein 166 and its Significance
Protein & Peptide Letters CDKN2B-AS1: An Indispensable Long Non-coding RNA in Multiple Diseases
Current Pharmaceutical Design Quinones Derived from Plant Secondary Metabolites as Anti-cancer Agents
Anti-Cancer Agents in Medicinal Chemistry MicroRNAs as Cancer Biomarkers
MicroRNA Recent Advances in Obesity Pharmacotherapy
Current Clinical Pharmacology Innovative Cancer Treatments that Augment Radiotherapy or Chemotherapy by the Use of Immunotherapy or Gene Therapy
Recent Patents on Anti-Cancer Drug Discovery